High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity

Neuroscience

Volumn 90, Issue 3, 1999, Pages 833-850

  Burrows, K B ^a,b   Meshul, C K ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Dopamine; Electron microscopy; Globus pallidus; Glutamate; Hyperthermia; Striatum

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID; METHAMPHETAMINE; NEUROTRANSMITTER; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN MITOCHONDRION; CONTROLLED STUDY; CORPUS STRIATUM; GABAERGIC SYSTEM; GLOBUS PALLIDUS; HYPERPYREXIA; HYPERTHERMIA; IMMUNOREACTIVITY; MALE; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; GLUTAMIC ACID; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE; MICROSCOPY, ELECTRON; PRESYNAPTIC TERMINALS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032895552     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00506-5     Document Type: Article

References (86)

1. Albin R. L., Young A. B., Penney J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
2. Anglade P., Mouatt-Prigent A., Agid Y., Hirsch E. C. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration. 5:1996;121-128.
3. Bowyer J. F., Davies D. L., Schmued L., Broening H. W., Newport G. D., Slikker W. Jr., Holson R. R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmac. exp. Ther. 268:1994;1571-1580.
4. Bowyer J. F., Tank A. W., Newport G. D., Slikker W. J., Ali S. F., Holson R. R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J. Pharmac. exp. Ther. 260:1992;817-824.
5. Buckman J. and Meshul C., Unpublished observation.
6. Burrows K. B., Meshul C. K. High-dose methamphetamine alters GABA immunocytochemistry in caudate and globus pallidus. Soc. Neurosci. Abstr. 23:1997;2144.
7. Burrows K. B., Meshul C. K. Methamphetamine alters presynaptic glutamate immunoreactivity in the caudate nucleus and motor cortex. Synapse. 27:1997;133-144.
8. Calabresi P., Mercuri N. B., Sancessaro G., Bernardi G. Electrophysiology of dopamine denervated striatal neurons: implications for Parkinson's disease. Brain. 116:1993;433-452.
9. Callaway C. W., Clark R. F. Hyperthermia in psychostimulant overdose. Ann. Emerg. Med. 24:1994;68-76.
10. Chan P., Di Monte D. A., Luo J. J., DeLanney L. E., Irwin I., Langston J. W. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62:1994;2484-2487.
11. Commins D. L., Seiden L. S. α-Methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex. Brain Res. 365:1986;15-20.
12. Craig A. L., Kupferberg H. J. Hyperthermia in D-amphetamine toxicity in aggregated mice of different strains. J. Pharmac. exp. Ther. 180:1972;616-624.
13. Dubé L., Smith A. D., Bolam J. P. Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum. J. comp. Neurol. 267:1988;455-471.
14. Eisch A. J., Gaffney M., Weihmuller F. B., O'Dell S. J., Marshall J. F. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res. 598:1992;321-326.
15. Eisch A. J., Marshall J. F., Slikker W. J., Schmued L. C. Methamphetamine-induced damage to cortical neurons is indicated by a newly-developed fluorescent tag. Soc. Neurosci. Abstr. 22:1996;1915.
16. Eisch A. J., O'Dell S. J., Marshall J. F. Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine. Synapse. 22:1996;217-225.
17. Ellison G., Switzer R. C. III Dissimilar patterns of degeneration in brain following four different addictive stimulants. NeuroReport. 5:1993;17-20.
18. Farooqui A. A., Haun S. E. and Horrocks L. A. (1994) Ischemia and hypoxia. In Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, 5th edn (ed. Siegal G. J.), pp. 867-883. Raven, New York.
19. Feller D. J., Young E. R., Riggan J. P., Stuart J., Crabbe J. C. Serotonin and genetic differences in sensitivity and tolerance to ethanol hypothermia. Psychopharmacology. 112:1993;331-338.
20. Fibiger H. C., McGeer E. G. Effect of acute and chronic methamphetamine treatment on tyrosine hydroxylase activity in brain and adrenal medulla. Eur. J. Pharmac. 16:1971;176-180.
21. Fleckenstein A. E., Gibb J. W., Hanson G. R. Acute effects of methamphetamine on tryptophan hydroxylase activity and oxygen radical formation in rat brain: role of hyperthermia. Soc. Neurosci. Abstr. 22:1996;2077.
22. Gerfen R. C., McGinty J. F., Young W. S. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 11:1991;1016-1031.
23. Gerlach M., Ben-Shacher D., Riederer P., Youdim M. B. H. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
24. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. neural Transm. 103:1996;987-1041.
25. Hanson G. R., Merchant K. M., Letter A. A., Bush L., Gibb J. W. Methamphetamine-induced changes in the striatal-nigral dynorphin system: role of D1 and D2 receptors. Eur. J. Pharmac. 144:1987;245-246.
26. Hefti F., Melamed E., Wurtman R. J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res. 195:1980;123-137.
27. Hepler J. R., Toomim C. S., McCarthy K. D., Conti F., Battaglia G., Rustioni A., Petrusz P. Characterization of antisera to glutamate and aspartate. J. Histochem. Cytochem. 36:1988;13-22.
28. Hill J. M. Iron concentration reduced in ventral pallidum, globus pallidus, and substantia nigra by GABA-transaminase inhibitor, gamma-vinyl GABA. Brain Res. 342:1985;18-25.
29. Hotchkiss A., Morgan M. E., Gibb J. W. The long term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activity. Life Sci. 25:1979;1373-1378.
30. Ingham C. A., Hood S. H., Arbuthnott G. W. A light and electron microscopical study of enkephalin-immunoreactive structures in the rat neostriatum after removal of the nigrostriatal dopaminergic pathway. Neuroscience. 42:1991;715-730.
31. Ingham C. A., Hood S. H., Mijnster M. J., Baldock R. A., Arbuthnott G. W. Plasticity of striatopallidal terminals following unilateral lesion of the dopaminergic nigrostriatal pathway: a morphological study. Expl Brain Res. 116:1997;39-49.
32. Ingham C. A., Hood S. H., van Maldegem B., Weenink A., Arbuthnott G. W. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Expl Brain Res. 93:1993;17-27.
33. Javoy-Agid F., Ploska A., Agid Y. Microtopography of tyrosine hydroxylase, glutamic acid decarboxylase, and choline acetyl transferase in the substantia nigra and ventral tegmental area of control and parkinsonian brains. J. Neurochem. 37:1981;1218-1227.
34. Jellinger K. (1988) Pathology of Parkinson's syndrome. In Handbook of Experimental Psychology (ed. Calne D. B.), pp. 47-112. Springer, New York.
35. Jicha G. A., Salamone J. D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms. J. Neurosci. 11:1991;3822-3829.
36. Jordan S. C., Hampson F. Amphetamine poisoning associated with hyperpyrexia. Br. med. J. 2:1960;844.
37. Kao T. Y., Chio C. C., Lin M. T. Hypothalamic dopamine release and local cerebral blood flow during onset of heatstroke in rats. Stroke. 25:1994;2483-2487.
38. Kincaid A. E., Albin R. L., Newman S. W., Penney J. B., Young A. B. 6-Hydroxydopamine lesions of the nigrostriatal pathway alter the expression of glutamate decarboxylase messenger RNA in rat globus pallidus projection neurons. Neuroscience. 51:1992;705-718.
39. Klockgether T., Turski L. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci. 12:1989;285-286.
40. Knochel J. P. Heat stroke and related heat stress disorders. Dis. Month. 35:1989;305-377.
41. Licata F., Li Volsi G., Ciranna L., Maugeri G., Santangelo F. 5-Hydroxytryptamine modifies neuronal responses to glutamate in the red nucleus of the rat. Expl Brain Res. 118:1998;61-70.
42. Lin M. T., Kao T. Y., Chio C. C., Jin Y. T. Dopamine depletion protects striatal neurons from heatstroke-induced ischemia and cell death in rats. Am. J. Physiol. 269:1995;H487-H490.
43. Lindefors N., Brodin E., Tossman U., Segovia J., Ungerstedt U. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation. Expl Brain Res. 74:1989;527-534.
44. Mamounsa L. A., Mullen C. A., O'Hearn E., Milliver M. E. Dual serotonergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J. comp. Neurol. 314:1991;558-586.
45. Marek G. J., Vosmer G. L., Seiden L. S. Pargyline increases 6-hydroxydopamine levels in the neostriatum of methamphetamine-treated rats. Pharmac. Biochem. Behav. 36:1990;187-190.
46. Marshall J. F., Navarrete R. J. Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment. Brain Res. 534:1990;348-351.
47. McGeorge A. J., Faull R. L. M. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537.
48. Melega W. P., Lacan G., Raleigh M. J., Datt A., Harvey D. C. Globus pallidus and substantia nigra iron and ferritin immunoreactivities increase in the vervet monkey after methamphetamine exposure. Soc. Neurosci. Abstr. 23:1997;2146.
49. Meshul C. K., Emre N., Nakamura C. M., Allen C. A., Donohue M. K. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience. 88:1998;1-16.
50. Meshul C. K., Stallbaumer R. K., Taylor B., Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 648:1994;181-195.
51. Meshul C. K., Tan S. E. Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity. Synapse. 18:1994;205-217.
52. Miller W. C. and DeLong M. R. (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of Parkinsonism. In The Basal Ganglia II (eds Carpenter M. B. and Jayarman A.), pp. 415-427. Plenum, New York.
53. Mitchell I. J., Clarke C. E., Boyce S., Robertson R. G., Peggs D., Sambrook M. A., Crossman A. R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 32:1989;213-226.
54. Oestreicher E., Sengstock G. J., Riederer P., Olanow C. W., Dunn A. J., Arendash G. W. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660:1994;8-18.
55. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic, Sydney.
56. Perry T. L., Javoy-Agid F., Agid Y., Fibiger H. C. Striatal GABAergic neuronal activity is not reduced in Parkinson's disease. J. Neurochem. 40:1983;1120-1123.
57. Phend K. D., Weinberg R. J., Rustioni A. Techniques to optimize post-embedding single and double staining for amino acid neurotransmitters. J. Histochem. Cytochem. 40:1992;1011-1020.
58. Pu C., Broening H. W., Vorhees C. V. Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex. Synapse. 23:1996;328-334.
59. Pu C., Fisher J. E., Cappon G. D., Vorhees C. V. The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum. Brain Res. 649:1994;217-224.
60. Ricaurte G. A., Schuster C. R., Seiden L. S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in rat brain. Brain Res. 193:1980;153-163.
61. Ritter J. K., Schmidt C. J., Gibb J. W., Hanson G. R. Increases in substance P-like immunoreactivity within striatal-nigral structures after subacute methamphetamine treatment. J. Pharmac. exp. Ther. 229:1984;487-492.
62. Rowlands G. J., Roberts P. J. Activation of dopamine receptors inhibits calcium-dependent glutamate release from corticostriatal terminals in vitro. Eur. J. Pharmac. 62:1980;241-242.
63. Ryan L. J., Linder J. C., Martone M. E., Groves P. M. Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res. 518:1990;67-77.
64. Ryan L. J., Martone M. E., Linder J. C., Groves P. M. Continuous amphetamine administration induces tyrosine hydroxylase immunoreactive patches in the adult neostriatum. Brain Res. Bull. 21:1988;133-137.
65. Sastry S., Arendash G. W. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex. Neuroscience. 67:1995;649-666.
66. Schmued L. C., Bowyer J. F. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res. 759:1997;135-140.
67. Schultz W., Ungerstedt U. Short-term increase and long-term reversion of striatal cell activity after degeneration of the nigrostriatal dopamine system. Expl Brain Res. 33:1978;159-171.
68. Segovia J., Garcia-Munoz M. Changes in the activity of GAD in the basal ganglia of the rat after striatal dopaminergic denervation. Neuropharmacology. 26:1987;1449-1451.
69. Seiden L. S., Commins D. L., Vosmer G. L., Axt K. J., Marek G. J. Neurotoxicity in dopamine and 5-HT terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. Ann. N. Y. Acad. Sci. 537:1988;161-172.
70. Seiden L. S., Fishman M. W. and Schuster C. R. (1975/76) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Dep. 1, 215-219.
71. Seiden L. S., Vosmer G. L. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmac. Biochem. Behav. 21:1984;29-31.
72. Smith A. D., Bolam J. P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci. 13:1990;259-265.
73. Stephans S. E., Yamamoto B. K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 17:1994;203-209.
74. Thal L. J., Sharpless N. S., Hirschhorn I. D., Horowitz S. G., Makman M. H. Striatal met-enkephalin concentration increases following nigrostriatal denervation. Biochem. Pharmac. 32:1983;3297-3301.
75. Tossman U., Segovia J., Ungerstedt U. Extracellular levels of amino acids in striatum and globus pallidus of 6-hydroxydopamine-lesioned rats measured with microdialysis. Acta physiol. scand. 127:1986;547-551.
76. van Luijtelaar M., Tonnaer J., Steinbusch H. Aging of the serotonergic system in the rat forebrain: an immunocytochemical and neurochemical study. Neurobiol. Aging. 13:1992;201-215.
77. Vernier P., Julien J., Rataboul P., Fourrier O., Feuerstein C., Mallet J. Similar time course changes in striatal levels of glutamic acid decarboxylase and preproenkephalin mRNA following dopaminergic deafferentation in the rat. J. Neurochem. 51:1988;1375-1380.
78. Voorn P., Roest G., Groenewegwn H. J. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412:1987;391-396.
79. Wagner G. C., Ricaurte G. A., Seiden L. S., Schuster C. R., Miller R. J., Westly J. Long-lasting depletion of striatal dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 171:1980;151-160.
80. Wallace T., Vorhees C. V., Gudelsky G. Methamphetamine induces a delayed increase in hydroxyl radical formation in the rat striatum. Soc. Neurosci. Abstr. 23:1997;2141.
81. Wang J. Q., McGinty J. F. Acute methamphetamine-induced zif/268, preprodynorphin, and preproenkephalin mRNA expression in rat striatum depends on activation of NMDA and kainate/AMPA receptors. Brain Res. Bull. 39:1996;349-357.
82. Weihmuller F. B., O'Dell S. J., Marshall J. F. Alterations in striatal glutamate receptors following 6-OHDA-induced damage to the nigrostriatal dopamine neurons. Soc. Neurosci. Abstr. 19:1993;1678.
83. Wilson J. M., Kalasinsky K. S., Levey A. I., Bergeron C., Reiber G., Anthony R. M., Schmunk G. A., Shannak K., Haycock J. W., Kish S. J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med. 2:1996;699-703.
84. Yamamoto B. K., Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 58:1992;1736-1742.
85. Yamamoto B. K., Gudelsky G. A. and Stephans S. E. (1998) Amphetamine neurotoxicity: roles for dopamine, glutamate, and oxidative stress. In Neurochemical Markers of Degenerative Diseases and Drug Addiction (eds Qureshi G. A., Parvez H., Caudy P. and Parvez S.), pp. 223-244. VSP, Utrecht, The Netherlands.
86. Yamamoto B. K., Zhu W. Methamphetamine, free radicals, and the production of oxidative stress. Soc. Neurosci. Abstr. 23:1997;2141.